ReviewInfectious disease reports2017
Resistance to Colistin in
Review in Infectious disease reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 26 citations in OpenAlex.
- "CORE" a new assay for rapid identification ofFrontiers in microbiology · 2023Article
- The Acquisition of Colistin Resistance Is Associated to the Amplification of a Large Chromosomal Region inInternational journal of molecular sciences · 2021Article
- Contribution of Time, Taxonomy, and Selective Antimicrobials to Antibiotic and Multidrug Resistance in Wastewater Bacteria.Environmental science & technology · 2020Article
- Lipid A profiling and metabolomics analysis of paired polymyxin-susceptible and -resistant MDR Klebsiella pneumoniae clinical isolates from the same patients before and after colistin treatment.The Journal of antimicrobial chemotherapy · 2020Article
- Ceftolozane/Tazobactam and Ceftazidime/Avibactam for Multidrug-Resistant Gram-Negative Infections in Immunocompetent Patients: A Single-Center Retrospective Study.Antibiotics (Basel, Switzerland) · 2020Article
- Global trends and current status in colistin resistance research: a bibliometric analysis (1973-2019).F1000Research · 2020Article
- Treatment Options for Colistin ResistantJournal of clinical medicine · 2019Review
- Risk Factors Affecting Patterns of Antibiotic Resistance and Treatment Efficacy in Extreme Drug Resistance in Intensive Care Unit-Acquired Klebsiella Pneumoniae Infections: A 5-Year Analysis.Medical science monitor : international medical journal of experimental and clinical research · 2019Article
- Molecular Epidemiological Insights into Colistin-Resistant and Carbapenemases-Producing ClinicalInfection and drug resistance · 2019Article
- Susceptibility of VirulentMicroorganisms · 2018Article
- Risk Factors for Colistin Resistance among Gram-Negative Rods and Klebsiella pneumoniae Isolates.Journal of clinical microbiology · 2018Article
- Genomic Characterization of Nonclonal mcr-1-Positive Multidrug-Resistant Klebsiella pneumoniae from Clinical Samples in Thailand.Microbial drug resistance (Larchmont, N.Y.) · 2018Article
- Synergistic Activity of Colistin in Combination With Resveratrol Against Colistin-Resistant Gram-Negative Pathogens.Frontiers in microbiology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The global rise of multidrug-resistant gram-negative bacteria represents an increasing threat to patient safety. From the first observation of a carbapenem-resistant gram-negative bacteria a global spread of extended-spectrum beta-lactamases and carbapenemases producing
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.